Stem Cell Therapy for the Knee
For many people with debilitating knee pain, treatment options are limited. A new, cutting-edge therapy involves the injection of stem cells into the damaged or injured knee joint.
For many people with debilitating knee pain, treatment options are limited. A new, cutting-edge therapy involves the injection of stem cells into the damaged or injured knee joint.
Stem cell therapy takes advantage of the body’s own natural ability to repair itself. The physician injects stem cells from bone marrow, amniotic fluid, or adipose tissue into your body. These cells have potent anti-inflammatory properties, similar to corticosteroids. However, stem cells have many more benefits. Cortisone and other drugs provide only temporary relief of pain, whereas stem cells actually restore damaged, degenerated, and injured tissue and structures. The growth factors in stem cells help replace damaged cells. In addition, stem cells have hyaluronic acid, which will lubricate the knee joint, restoring mobility and easing pain.
Stem cell therapy is proven effective and safe. Benefits include:
Amniotic cell donors go through a strenuous screening process, which is monitored by the Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB). More than 10,000 stem cell injections have been performed with no report of adverse side effects or reactions.
Conditions treated using stem cell injections include:
Patients with severe degenerative arthritis of the knee are not suitable candidates for stem cell therapy. However, patients with other knee conditions could benefit from these injections. Candidates are:
In a recent study, researchers studied 18 patients with knee osteoarthritis who received intraarticular injections of autologous adipose tissue derived MSCs. In phase one of the study, all of the patients received three doses: a low dose, a mid-dose, and a high dose. In phase two of the study, only 9 patients received the high dose regimen. Outcomes after 6 months were evaluated using the Western Ontario and McMaster Universities Osteoarthritis index. Secondary outcomes involved various evaluations (arthroscopic, radiological, clinical, and histological).
In the study, no patients had treatment-related adverse events. In the high dose group, all patients had improved scores at 6 months after injection. In addition, the size of the cartilage defect decreased while the volume of the cartilage increased in the medial femoral and tibial condyles. When examined by arthroscopy, the size of the cartilage defect decreased. Overall, results showed that MSCs improve knee function and pain and also reduced cartilage defects when given in high doses.
Jo CH, Lee YG, Shin WH, et al. (2014). Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells, 32(5), 1254-1266.